Laura Gómez-Virgilio

Dr. Laura Gómez-Virgilio

Universidad Nacional Autónoma de México, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
Maria-del-Carmen Silva-LuceroMaria-del-Carmen Silva-Lucero
Maria-del-Carmen Silva-Lucero
DFDiego-Salvador Flores-Morelos
Diego-Salvador Flores-Morelos
JGJazmin Gallardo-Nieto
Jazmin Gallardo-Nieto
Gustavo Lopez-ToledoGustavo Lopez-Toledo
Gustavo Lopez-Toledo
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
Autophagy is a highly conserved lysosomal degradation pathway active at basal levels in all cells. However, under stress conditions, such as a lack of nutrients or trophic factors, it works as a survival mechanism that allows the generation of metabolic precursors for the proper functioning of the cells until the nutrients are available. Neurons, as post-mitotic cells, depend largely on autophagy to maintain cell homeostasis to get rid of damaged and/or old organelles and misfolded or aggregated proteins. Therefore, the dysfunction of this process contributes to the pathologies of many human diseases. Furthermore, autophagy is highly active during differentiation and development. In this review, we describe the current knowledge of the different pathways, molecular mechanisms, factors that induce it, and the regulation of mammalian autophagy. We also discuss its relevant role in development and disease. Finally, here we summarize several investigations demonstrating that autophagic abnormalities have been considered the underlying reasons for many human diseases, including liver disease, cardiovascular, cerebrovascular diseases, neurodegenerative diseases, neoplastic diseases, cancers, and, more recently, infectious diseases, such as SARS-CoV-2 caused COVID-19 disease.

30 September 2014 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
SDSteven DeRosa
Steven DeRosa
MMMarco Antonio Meraz-Ríos
Marco Antonio Meraz-Ríos

21 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Daniel Marrero-RodriguezDaniel Marrero-Rodriguez
Daniel Marrero-Rodriguez
KTKeiko Taniguchi-Ponciano
Keiko Taniguchi-Ponciano
MSMalayannan Subramaniam
Malayannan Subramaniam
John R. HawseJohn R. Hawse
John R. Hawse
KPKevin S. Pitel
Kevin S. Pitel
MSMauricio Salcedo
Mauricio Salcedo
Cervical cancer (CC) is associated with alterations in immune system balance, which is primarily due to a shift from Th1 to Th2 and the unbalance of Th17/Treg cells. Usingin silicoDNA copy number analysis, we have demonstrated that ~20% of CC samples exhibit gain of 8q22.3 and 19q13.31; the regions of the genome that encodes the KLF10 and PSG genes, respectively. Gene expression studies demonstrated that there were no alterations in KLF10 mRNA expression, whilst the PSG2 and −5 genes were up-regulated by 1.76 and 3.97-fold respectively in CC compared to normal tissue controls. siRNA and ChIP experiments in SiHa cells have demonstrated that KLF10 participates in immune response through regulation of IL6, IL25 and PSG2 and PSG5 genes. Using cervical tissues from KLF10−/−mice, we have identified down-regulation of PSG17, −21 and −23 and IL11. These results suggest that KLF10 may regulate immune system response genes in cervical cancer among other functions. KLF10 and PSG copy number variations and alterations in mRNA expression levels could represent novel molecular markers in CC.

29 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
MVMireya Velazquez-Paniagua
Mireya Velazquez-Paniagua
LCLucero Cuazozon-Ferrer
Lucero Cuazozon-Ferrer
Maria-del-Carmen Silva-LuceroMaria-del-Carmen Silva-Lucero
Maria-del-Carmen Silva-Lucero
AGAndres-Ivan Gutierrez-Malacara
Andres-Ivan Gutierrez-Malacara
Maria-del-Carmen Cardenas-AguayoMaria-del-Carmen Cardenas-Aguayo
Maria-del-Carmen Cardenas-Aguayo
This review article focuses on von Hippel–Lindau (VHL) disease, a rare genetic disorder characterized by the development of tumors and cysts throughout the body. It discusses the following aspects of the disease. Genetics: VHL disease is caused by mutations in the VHL tumor suppressor gene located on chromosome 3. These mutations can be inherited or occur spontaneously. This article details the different types of mutations and their associated clinical features. Pathophysiology: The underlying cause of VHL disease is the loss of function of the VHL protein (pVHL). This protein normally regulates hypoxia-inducible factors (HIFs), which are involved in cell growth and survival. When pVHL is dysfunctional, HIF levels become elevated, leading to uncontrolled cell growth and tumor formation. Clinical Manifestations: VHL disease can affect various organs, including the brain, spinal cord, retina, kidneys, pancreas, and adrenal glands. Symptoms depend on the location and size of the tumors. Diagnosis: Diagnosis of VHL disease involves a combination of clinical criteria, imaging studies, and genetic testing. Treatment: Treatment options for VHL disease depend on the type and location of the tumors. Surgery is the mainstay of treatment, but other options like radiation therapy may also be used. Challenges: This article highlights the challenges in VHL disease management, including the lack of effective therapies for some tumor types and the need for better methods to monitor disease progression. In conclusion, we emphasize the importance of ongoing research to develop new and improved treatments for VHL disease.

1 May 2017 in Archives of Medical Research
Verified
Journal Article
Closed access
Daniel Marrero-RodriguezDaniel Marrero-Rodriguez
Daniel Marrero-Rodriguez
HCHugo Arreola-De la Cruz
Hugo Arreola-De la Cruz
KTKeiko Taniguchi-Ponciano
Keiko Taniguchi-Ponciano
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
VHVictor Huerta-Padilla
Victor Huerta-Padilla
MSMauricio Salcedo
Mauricio Salcedo

Verified
Journal Article
Open access
PDF file
Laura Gómez-VirgilioLaura Gómez-Virgilio
Laura Gómez-Virgilio
ALAlejandro Luarte
Alejandro Luarte
DPDaniela Paz Ponce
Daniela Paz Ponce
BJBárbara Bruna Jara
Bárbara Bruna Jara
MBMaría Isabel Behrens
María Isabel Behrens
Among all the proposed pathogenic mechanisms to understand the etiology of Alzheimer’s disease (AD), increased oxidative stress seems to be a robust and early disease feature where many of those hypotheses converge. However, despite the significant lines of evidence accumulated, an effective diagnosis and treatment of AD are not yet available. This limitation might be partially explained by the use of cellular and animal models that recapitulate partial aspects of the disease and do not account for the particular biology of patients. As such, cultures of patient-derived cells of peripheral origin may provide a convenient solution for this problem. Peripheral cells of neuronal lineage such as olfactory neuronal precursors (ONPs) can be easily cultured through non-invasive isolation, reproducing AD-related oxidative stress. Interestingly, the autofluorescence of key metabolic cofactors such as reduced nicotinamide adenine dinucleotide (NADH) can be highly correlated with the oxidative state and antioxidant capacity of cells in a non-destructive and label-free manner. In particular, imaging NADH through fluorescence lifetime imaging microscopy (FLIM) has greatly improved the sensitivity in detecting oxidative shifts with minimal intervention to cell physiology. Here, we discuss the translational potential of analyzing patient-derived ONPs non-invasively isolated through NADH FLIM to reveal AD-related oxidative stress. We believe this approach may potentially accelerate the discovery of effective antioxidant therapies and contribute to early diagnosis and personalized monitoring of this devastating disease.